» Articles » PMID: 34870138

Metabolic Causes and Consequences of Nonalcoholic Fatty Liver Disease (NAFLD)

Overview
Journal Metabol Open
Specialty Endocrinology
Date 2021 Dec 6
PMID 34870138
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Nonalcoholic fatty liver disease (NAFLD) is a multifactorial metabolic disorder that was first described in 1980. It has been prevalent and on the rise for many years and is associated with other metabolic disorders such as obesity and type 2 diabetes mellitus (T2DM). NAFLD can be best described as a metabolic dysfunction that stems from insulin resistance-induced hepatic lipogenesis. This lipogenesis increases oxidative stress and hepatic inflammation and is often potentiated by genetic and gut microbiome dysfunction. As NAFLD progresses from simple steatosis to non-alcoholic steatohepatitis (NASH) and to cirrhosis and hepatocellular carcinoma (HCC), the odds of complications including cardiovascular disease (CVD), chronic kidney disease (CKD), and overall mortality increase. The aim of this review is to describe the metabolic causes and consequences of NAFLD while examining the risks that each stage of NAFLD poses. In this review, the etiology of "lean" NAFLD, the impact of obesity, T2DM, genetics, and microbiome dysbiosis on NAFLD progression are all explored. This review will also discuss the core issue behind the progression of NAFLD: insulin resistance (IR). Upon describing the causes and consequences of NAFLD, the effectiveness of diet modification, lifestyle changes, and glucagon-like peptide 1 receptor (GLP-1) agonists to retard NAFLD progression and stem the rate of complications is examined.

Citing Articles

Exploring the mechanism of SLXG for treating nonalcoholic fatty liver disease based on network pharmacology and molecular docking.

Wang Y, Wang J, Chen Z, Liu B, Wang W, Li Y Medicine (Baltimore). 2025; 104(6):e40255.

PMID: 39928768 PMC: 11813010. DOI: 10.1097/MD.0000000000040255.


Identification of Interactive Genetic Loci Linked to Insulin Resistance in Metabolic Syndrome-An Update.

Elfaki I, Mir R, Elnageeb M, Hamadi A, Alharbi Z, Bedaiwi R Medicina (Kaunas). 2025; 61(1).

PMID: 39859066 PMC: 11767019. DOI: 10.3390/medicina61010083.


Ellagic Acid Modulates Necroptosis, Autophagy, Inflammations, and Stress to Ameliorate Nonalcoholic Liver Fatty Disease in a Rat Model.

Li Z, Li J, He S, Chen J, Deng C, Duan J Food Sci Nutr. 2025; 13(1):e4694.

PMID: 39830906 PMC: 11742184. DOI: 10.1002/fsn3.4694.


Biomarkers and Seaweed-Based Nutritional Interventions in Metabolic Syndrome: A Comprehensive Review.

Valado A, Cunha M, Pereira L Mar Drugs. 2024; 22(12).

PMID: 39728125 PMC: 11677938. DOI: 10.3390/md22120550.


From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome - current insights and future directions.

Basil B, Myke-Mbata B, Eze O, Akubue A Clin Diabetes Endocrinol. 2024; 10(1):39.

PMID: 39617908 PMC: 11610122. DOI: 10.1186/s40842-024-00187-4.


References
1.
Targher G, Byrne C, Lonardo A, Zoppini G, Barbui C . Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016; 65(3):589-600. DOI: 10.1016/j.jhep.2016.05.013. View

2.
Younossi Z, Anstee Q, Marietti M, Hardy T, Henry L, Eslam M . Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017; 15(1):11-20. DOI: 10.1038/nrgastro.2017.109. View

3.
Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M . Autophagy regulates lipid metabolism. Nature. 2009; 458(7242):1131-5. PMC: 2676208. DOI: 10.1038/nature07976. View

4.
Matteoni C, Younossi Z, Gramlich T, Boparai N, Liu Y, McCullough A . Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999; 116(6):1413-9. DOI: 10.1016/s0016-5085(99)70506-8. View

5.
Smith A, Baumgartner K, Bositis C . Cirrhosis: Diagnosis and Management. Am Fam Physician. 2019; 100(12):759-770. View